Effect of a dietary supplement on high-normal blood pressure
| ISRCTN | ISRCTN13991711 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN13991711 |
| Protocol serial number | 235/T-11 |
| Sponsor | BioCC OÜ |
| Funder | Bio-Competence Centre of Healthy Dairy Products LLC Project EU 30002 |
- Submission date
- 23/01/2015
- Registration date
- 06/02/2015
- Last edited
- 07/02/2022
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Circulatory System
Plain English summary of protocol
Background and study aims
Increased blood pressure (hypertension) is widely accepted as a major cardiovascular risk factor. The reduction in blood pressure reduces the prevalence of cardiovascular diseases and stroke. Even a 2 mmHg lower usual SBP would lead to about 10% lower stroke mortality and about 7% lower mortality from ischaemic heart disease or other vascular causes in middle age and the reduction of SBP for 10 mmHg lower usual or 5 mmHg lower usual DBP would, in the long term, be associated with about 40% lower risk of stroke death and about 30% lower risk of death from vascular causes. The aim of this study is to assess a probiotic dietary supplement on blood pressure reduction.
Who can participate?
Generally healthy people, age 18–65 years, with an increase in blood pressure, who do not take medications.
What does the study involve?
The study population will be recruited from an already existing population (encoded) from the database. Additionally, participants will be recruited through media and social networks (e.g., Facebook), and e-mail lists of various professional associations. Participants will be randomly assigned to one of two arms for 8 weeks, followed by 2 weeks of washout: Lactobacillus plantarum TENSIA (150 mg per capsule) or control (placebo product in capsulated form containing microcellulose).
What are the possible benefits and risks of participating?
The study causes minimal inconveniences to participants. As blood samples are taken by an experienced nurse, the procedure is safe. However, there may be bruising and discomfort at the site of the blood test as with any blood test. The amounts of blood we are taking are small enough that they should not make you feel fatigue or cause anaemia. Study participants receive assessment of their health status and, if necessary, free consultation of a nutritionist and/or a specialist.
Where is the study run from?
Centre for Clinical and Physiological Research of the Bio-Competence Centre of Healthy Dairy Products LLC (Estonia)
When is the study starting and how long is it expected to run for?
April 2014 to June 2022
Who is funding the study?
BioCC OÜ (Estonia)
Who is the main contact?
Ms Merle Rätsep
merle.ratsep@tptak.ee
Contact information
Scientific
Kreutzwaldi str 1
Tartu
51014
Estonia
| Phone | +372 7 374175 |
|---|---|
| esongisepp@gmail.com |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Randomised controlled double-blind phase 2 study |
| Secondary study design | Randomised controlled trial |
| Study type | Participant information sheet |
| Scientific title | Effect of a dietary supplement containing Lactobacillus plantarum TENSIA on the subpopulation with high-normal blood pressure: a randomised controlled double-blind phase 2 study |
| Study acronym | TEN |
| Study objectives | The consumption of a dietary supplement containing Lactobacillus plantarum TENSIA helps to maintain the normal blood pressure by reducing high-normal (systolic) blood pressure |
| Ethics approval(s) | Ethics Review Committee on Human Research of the University of Tartu, 17/03/2014, reference number 235/T-11 |
| Health condition(s) or problem(s) studied | High-normal (130–139/85–89 mmHg) baseline blood pressure |
| Intervention | 1. Healthy volunteers will be randomly allocated according to a random number table to one of two study arms and will take one capsule per day for 8 weeks followed by 2 weeks of washout: 1.1. Lactobacillus plantarum TENSIA 150 mg/day (hydroxypropyl methylcellulose): 7000 million colony-forming units 1.2. Control: placebo product in capsulated form containing microcellulose 2. Blood pressure, waist circumference, and bodyweight will be measured 3. Participants will be asked to assess their wellbeing and gastrointestinal effects, and provide blood, urine and fecal samples at every visit |
| Intervention type | Supplement |
| Primary outcome measure(s) |
Change in systolic blood pressure (SBP) at 8 weeks from baseline: |
| Key secondary outcome measure(s) |
1. Change in SBP at 4 weeks from baseline |
| Completion date | 30/06/2022 |
Eligibility
| Participant type(s) | Healthy volunteer |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | All |
| Target sample size at registration | 300 |
| Total final enrolment | 23 |
| Key inclusion criteria | 1. Desire to participate 2. Age 18–65 years 3. High-normal (130–139/85–89 mmHg) screening blood pressure 4. Normal or not clinically significant deviations in safety laboratory values (clinical chemistry, blood count), white blood cell count <8800 million/L, high-sensitivity C-reactive protein <5 mg/L; fasting glucose <6.0mmol/L, serum creatinine in females <80 μmol/L, serum creatinine in males <106 μmol/L, glycated haemoglobin < 5.9% 5. No use of any concomitant treatment including blood pressure lowering drugs (e.g., angiotensin-converting-enzyme inhibitors, blockers of beta adrenergic receptors, calcium channel blockers and diuretics) and lipid-lowering drugs (e.g., statins, bile acid sequestrates, cholesterol absorption inhibitors, nicotinic acid) that could affect the evaluation of the efficacy and tolerability of the investigational study product within 1 month before the study start. 6. Signed informed consent 7. Willingness to maintain a stable diet and physical activity level |
| Key exclusion criteria | 1. History of any gastrointestinal disease 2. Use of any antimicrobial drug within past month 3. Use of any regular concomitant medication, including medical preparations, non-steroidal anti-inflammatory drugs and antioxidant vitamins 4. Food allergy 5. Diabetes and acute infection 6. Pregnancy or breastfeeding 7. SBP ≤ 129 mmHg and/or DBP ≤ 84 mmHg 7.1. Hypertension (≥140–159 / 90–99 mmHg) 7.2. History or clinical signs of cardiovascular abnormalities (e.g., stroke), particularly cardiac arrhythmia and bradycardia (pulse rate <50 beats per minute) |
| Date of first enrolment | 01/09/2014 |
| Date of final enrolment | 01/12/2020 |
Locations
Countries of recruitment
- Estonia
Study participating centre
Tartu
51014
Estonia
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan | Not provided at registration. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
| Study website | Study website | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
07/02/2022: The sponsor organisation has been changed from "Bio-Competence Centre of Healthy Dairy Products LLC (Estonia)" to "BioCC OÜ" and the plain English summary has been updated accordingly.
04/01/2022: The following changes have been made:
1. The final enrolment number has been added.
2. The intention to publish date has been changed from 31/12/2018 to 31/12/2022.
01/07/2019: The following changes were made to the trial record:
1. The recruitment end date was changed from 30/09/2018 to 01/12/2020.
2. The overall trial end date was changed from 31/12/2018 to 30/06/2022.
